These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1151655)

  • 41. The chiral synthesis and biochemical properties of electron rich phenolic sulfoxide analogs of sparsomycin.
    Flynn GA; Ash RJ
    Biochem Biophys Res Commun; 1990 Jan; 166(2):673-80. PubMed ID: 2405852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antitumor activity of the novel nitrosourea S10036 in rodent tumors.
    Filippeschi S; Colombo T; Bassani D; De Francesco L; Arioli P; D'Incalci M; Bartosek I; Guaitani A
    Anticancer Res; 1988; 8(6):1351-4. PubMed ID: 3064716
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aryl-2-halogenoalkylamines. XXII. Derivatives of phenoxyacetic acid: synthesis and antineoplastic activities.
    Artico M; Ross WC
    Biochem Pharmacol; 1968 Jun; 17(6):873-82. PubMed ID: 5661350
    [No Abstract]   [Full Text] [Related]  

  • 44. Antitumour activity and retinotoxicity of ethyldeshydroxy-sparsomycin in mice.
    Hofs HP; Wagener DJ; De Vos D; Ottenheijm HC; Winkens HJ; Bovee PH; De Grip WJ
    Eur J Cancer; 1995; 31A(9):1526-30. PubMed ID: 7577083
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aryl-2-halogenoalkylamines. 23. Derivatives of oxanilic acid and salicylic acid: synthesis and antineoplastic activities.
    Artico M; Ross WC
    Biochem Pharmacol; 1968 Jun; 17(6):883-91. PubMed ID: 5661351
    [No Abstract]   [Full Text] [Related]  

  • 46. Synthesis and biological activity of acronycine analogs.
    Schneider J; Evans EL; Grunberg E; Fryer RI
    J Med Chem; 1972 Mar; 15(3):266-70. PubMed ID: 5062070
    [No Abstract]   [Full Text] [Related]  

  • 47. Aryl-2-halogenoalkylamines. XXIV. Derivatives of o-, m- and p-aminophenol: synthesis and antineoplastic activities.
    Artico M; Ross WC
    Biochem Pharmacol; 1968 Jun; 17(6):893-8. PubMed ID: 5661352
    [No Abstract]   [Full Text] [Related]  

  • 48. The development of sparsomycin as an anti-tumour drug.
    Ottenheijm HC; van den Broek LA
    Anticancer Drug Des; 1988 Mar; 2(4):333-7. PubMed ID: 3365303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Experimental antileukemic agents. Coralyne, analogs, and related compounds.
    Zee-Cheng KY; Paull KD; Cheng CC
    J Med Chem; 1974 Mar; 17(3):347-51. PubMed ID: 4811233
    [No Abstract]   [Full Text] [Related]  

  • 50. Preclinical pharmacokinetics of the antitumor antibiotic deshydroxy-sparsomycin in beagle dogs.
    Zylicz Z; Wagener DJ; Garzotto M; Vree TB; van der Kleijn E; van den Broek LA; Ottenheijm HC
    Anticancer Res; 1988; 8(6):1381-5. PubMed ID: 3218972
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and pharmacological screening of 1-chloro-3-(2-propynyloxy)-2-propanols and 2-((2-propynyloxy)methyl)oxiranes.
    Fugitt RB; Wu GS; Martinelli LC
    J Pharm Sci; 1973 Nov; 62(11):1894-6. PubMed ID: 4758098
    [No Abstract]   [Full Text] [Related]  

  • 52. Synthesis of potential antineoplastic agents. Substituted phenylcyclohexenes.
    Core SK; Lotspeich FJ
    J Med Chem; 1969 Mar; 12(2):334-6. PubMed ID: 4181946
    [No Abstract]   [Full Text] [Related]  

  • 53. Irreversible enzyme inhibitors. 173. Cure of Walker 256 ascites by reversible and irreversible inhibitors of dihydrofolic reductase derived from 1-(substituted-phenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazine.
    Baker BR; Vermeulen NM; Ashton WT; Ryan AJ
    J Med Chem; 1970 Nov; 13(6):1130-40. PubMed ID: 5479852
    [No Abstract]   [Full Text] [Related]  

  • 54. Chromophore-modified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemias.
    Cholody WM; Martelli S; Konopa J
    J Med Chem; 1992 Jan; 35(2):378-82. PubMed ID: 1732555
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis of potential antineoplastic agents. XIV. Some 2-substituted 2,3-dihydro-1h-perimidines.
    Wasulko W; Noble AC; Popp FD
    J Med Chem; 1966 Jul; 9(4):599-601. PubMed ID: 4165378
    [No Abstract]   [Full Text] [Related]  

  • 56. [Action of nitrosoalkylureas and the longevity of tumor-bearing animals].
    Krutova TV; Kondradov AA; Ostrovskaia LA
    Izv Akad Nauk SSSR Biol; 1983; (6):843-50. PubMed ID: 6655115
    [No Abstract]   [Full Text] [Related]  

  • 57. Potential antitumor agents. 38. 3-substituted 5-carboxamido derivatives of amsacrine.
    Denny WA; Atwell GJ; Baguley BC
    J Med Chem; 1983 Nov; 26(11):1619-25. PubMed ID: 6688829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential antitumor agents. Synthesis of bifunctional alpha-methylene-gamma-butyrolactones.
    Howie GA; Stamos IK; Cassady JM
    J Med Chem; 1976 Feb; 19(2):309-13. PubMed ID: 1249811
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Some structural relationships among cytotoxic and antitumor benzophenanthridine alkaloid derivatives.
    Stermitz FR; Larson KA; Kim DK
    J Med Chem; 1973 Aug; 16(8):939-40. PubMed ID: 4784311
    [No Abstract]   [Full Text] [Related]  

  • 60. Importance of the hydrophobic sulfoxide substituent on nontoxic analogs of sparsomycin.
    Ash RJ; Fite LD; Beight DW; Flynn GA
    Antimicrob Agents Chemother; 1984 Apr; 25(4):443-5. PubMed ID: 6375553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.